MethaCholine Bronchoprovocation Study (MeCIS)

Summary

The purpose of this research is to evaluate the methacholine challenge test as an accurate indicator of asthma in patients receiving treatment for asthma. Phase 1 on the study compares methacholine challenge test results from asthma patients to those from people who do not have asthma. In phase 2, test results for people with asthma on low dose inhaled corticosteroid will be compared to results on high dose inhaled corticosteroids. Both males and females with stable asthma (asthma participants) and without asthma (controls) enrolled. Participants will be between 12 and 69 years of age.

Conditions

• Asthma

Interventions

DRUG

fluticasone

Inhaled corticosteroid approved for treatment of asthma

Sponsors & Collaborators

• Washington University School of Medicine

  collaborator OTHER

• St. Louis University

  collaborator OTHER

• Long Island Jewish Medical Center

  collaborator OTHER

• North Shore University Hospital

  collaborator OTHER

• Baylor College of Medicine

  collaborator OTHER

• University of Vermont

  collaborator OTHER

• Nemours Children's Clinic

  collaborator OTHER

• University of Florida

  collaborator OTHER

• Indiana University

  collaborator OTHER

• Ohio State University

  collaborator OTHER

• NYU Langone Health

  collaborator OTHER

• University of Missouri-Columbia

  collaborator OTHER

• Northwestern University

  collaborator OTHER

• Louisiana State University Health Sciences Center in New Orleans

  collaborator OTHER

• University of Miami

  collaborator OTHER

• University of South Florida

  collaborator OTHER

• University of California, San Diego

  collaborator OTHER

• National Jewish Health

  collaborator OTHER

• Duke University

  collaborator OTHER

• Johns Hopkins Bloomberg School of Public Health

  lead OTHER

Principal Investigators

• Kaharu Sumino, MD · St. Louis Asthma Clinical Research Center

Study Design

Allocation

RANDOMIZED

Purpose

DIAGNOSTIC

Masking

QUADRUPLE

Model

CROSSOVER

Eligibility

Min Age

12 Years

Max Age

69 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2009-01-31

Primary Completion

2010-02-28

Completion

2010-02-28

Countries

• United States

Study Locations